According to the CEO of Parto Negar Persia Company, Dr. Mohammad Reza Ay, GammaPen system, a hand-held device with the capability of detection and localization of sentinel lymph nodes in breast cancer and for some masculine types of cancers, successfully passed the clinical tests and obtained the production license from the National Medical Device Directorate. An article on the device performance was also published in the international journal of Annals of Nuclear Medicine.
